UnitedHealth Just Proved Warren Buffett Right -- Again

UnitedHealth reported better-than-expected Q1 revenue and earnings and raised full-year guidance, with its medical cost ratio improving to 83.9% from 84.8% year over year. The article frames the results as evidence of a turnaround after last year's setbacks, including a withdrawn outlook, CEO departure, and DOJ scrutiny. It also highlights Warren Buffett's $1.6 billion stake as validation of the company's underlying fundamentals.

Analysis

The market is likely underestimating how quickly pricing discipline can repair earnings power in a managed-care name once utilization stops worsening faster than rate actions. The key second-order effect is that a visible margin inflection at UNH often compresses the valuation discount applied to the entire managed-care complex, because investors stop treating margin pressure as secular and start underwriting it as cyclical normalization. That matters most for peers with similar book-of-business exposure, where a rerating can happen before full operating leverage shows up in reported numbers.

The bigger takeaway for positioning is that the recent controversy likely flushed out weak holders, which can make the next few quarters mechanically cleaner even if fundamentals improve only gradually. However, this is still a hostage-to-future-guidance story: one adverse comment on utilization, MA pricing, or regulatory pressure can reverse the narrative fast because the stock now trades on trust in management execution rather than just on earnings.

CMS is the main swing factor over a 6-12 month horizon, not the latest quarter. If rate-setting or reimbursement assumptions stay constructive, UNH can compound through 2026; if policy comes in below expectations again, the market will quickly re-price the recovery as a dead-cat bounce. The contrarian miss is that investors may be extrapolating one quarter of relief into a durable reset, when the real test is whether margins hold after the easy pricing benefit is absorbed.

Key Decisions for Investors

• Long UNH vs. a basket of managed-care peers for 3-6 months: buy UNH and short the weaker operator set on relative valuation, targeting a 10-15% spread if the turnaround narrative persists.
• Add to BRK.B on any post-earnings consolidation in UNH: Buffett-style “buy-the-dip” validation improves sentiment around high-quality value compounds; use a 6-12 month horizon with low downside if UNH gives back part of the move.
• Sell downside put spreads in UNH into strength for 1-3 months: the stock likely has a higher floor after the guidance reset, but implied vol should remain elevated enough to monetize if the earnings recovery is believed.
• Fade CMS on rallies over the next 1-2 quarters if the market is pricing in overly generous reimbursement assumptions: policy upside is now the key reverse-catalyst for UNH and the broader MA complex.